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Characteristics of NK cell activity in 
patients with systemic sclerosis
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João Carlos Tavares Brenol5, Luiz Fernando Jobim6, Ricardo Machado Xavier7
ABSTRACT
Introduction: Previous studies have shown an increased expression of natural killer (NK) cells in the peripheral blood 
of patients with systemic sclerosis (SSc). NK cells are part of innate immunity, recognizing infected cells through killer 
immunoglobulin-like receptors (KIR), which show marked polymorphism. A novel model has been proposed predict-
ing the activity of NK cells, evaluating whether there is excessive activation (EA), excessive inhibition (EI) or balance 
(B) (neutral). Objective: To evaluate the activity of NK cells in patients with SSc and compare it with that of a control 
group. Method: This study comprised 110 patients with SSc and 115 healthy controls. A novel model that predicts the 
activity of NK cells was used. For that, cells with their respective KIR/HLA-C and Bw4 ligands were considered. The 
activity of NK cells was de¿ ned as EA, EI, or B. Results: Our results showed that 63.5% of healthy controls had the 
KIR phenotype characterized by EI, as compared with 39.1% of the patients with SSc (P = 0.001). Considering only 
KIR2DL2-positive individuals, 34.7% of EI was found in healthy controls and 10.9% in patients with SSc (P < 0.001). 
Conclusion: In our study, the model that predicts the action of NK cells showed that healthy controls have higher fre-
quency of EI as compared with SSc patients, suggesting a protective effect of the EI pro¿ le against the development 
of SSc. These results suggest a potential role of NK cells in the pathogenesis of SSc, but further studies should be 
conducted to con¿ rm our data. 
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INTRODUCTION
Systemic sclerosis (SSc) is a rare autoimmune disease char-
acterized by endothelial dysfunction and tissue ¿ brosis. It 
is a diffuse connective tissue disease that can affect several 
organic systems, especially the digestive and respiratory sys-
tems. Systemic sclerosis has two presentation forms, limited 
and diffuse, which are differentiated based on the extension 
of skin involvement.1 Its major characteristics are excessive 
collagen deposition, vascular lesions, and changes in cellular 
and humoral immunity.2
There is evidence that certain genetic characteristics 
favor the progression of chronic inÀ ammation to ¿ brosis. 
Participation of the immune system has been suggested due 
to the presence of mononuclear cellular in¿ ltrates in lesions, 
abnormalities in T helper cells and in monocyte function,3 
release of several cytokines, and reduced activity of natural 
killer (NK) cells.4
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The NK cells have receptors, denominated ‘killer immuno-
globulin-like receptors’ (KIR), which belong to the family of 
the immunoglobulins present on cell surface. According to their 
functional groups, those receptors are classi¿ ed as inhibitory 
(prevent target cell lysis) or activatory (cause target cell lysis).5 
The inhibitory receptor recognizes the speci¿ c HLA class I 
antigen, preventing the attack of NK cells against normal cells; 
conversely, the activatory receptor is triggered when inhibi-
tory KIR receptors do not recognize the target cell, activating 
NK cells for destruction.6 The ability to attack ‘self’ cells that 
do not express HLA-I is known as ‘missing self-recognition’. 
That hypothesis has been supported by several independent 
observations, demonstrating that HLA antigens really protect 
cells against lysis by NK cells, providing negative signs that 
inhibit the activity of NK cells.7
Theoretically, any inhibitory ligand combination KIR-HLA 
should be able to neutralize activation. The function of NK cells 
is regulated by positive and negative signals transmitted by 
pairs of activatory and inhibitory receptors. In vivo, NK cells 
are controlled by inhibitory receptors for self HLA-I ligands.8 
Thus, effector functions occur only when activation signals can 
surpass inhibitory signaling. That is obtained through either the 
predominance of the activation of receptor-ligand interactions 
or lack of the inhibitory ligand of the receptor.9
A novel model has been recently proposed by Nelson et 
al.,10 predicting that, depending on the genotype, individuals 
could be classi¿ ed into one of three groups, according to the 
activity characteristics of their NK cells: 1) mainly controlled 
by inhibitory receptors (major inhibition); 2) controlled equally 
by inhibitory and activating receptors (relatively neutral); or 3) 
mainly controlled by activating receptors (major activation). 
Similarly, individuals lacking ligands for inhibitory receptors 
(such as homozygous for HLA-Cw group 1 or 2 ligands) will 
have fewer NK cells under inhibitory control than individuals 
with all ligands present.
So far, only two studies have assessed the activity of NK 
cells according to that novel model – one in diabetes11 and the 
other in psoriasis.12 Because of the scarcity of studies on the 
subject, this study aimed at assessing the activity of NK cells 
in a group of patients with SSc as compared to a control group. 
PATIENTS AND METHODS
All participants were instructed about this research. They 
provided written informed consent, and their decision did 
not affect the physician-patient relationship. This study was 
approved by the Ethics Committee of the Hospital de Clínicas 
de Porto Alegre (HCPA).
Patients
This study included 110 patients with SSc originating from 
the Rheumatology Outpatient Clinic of the HCPA. All 
patients had been diagnosed according to either the 1987 
American College of Rheumatology criteria13 or the LeRoy 
and Medsger’s criteria for the classi¿ cation of early SSc.14 
Patients with overlap syndromes with other diffuse connec-
tive tissue diseases (except for Sjögren’s syndrome) were 
excluded from the study.
Controls
The control group comprised 115 unrelated individuals, 
originating from the Immunology Service of the HCPA, who 
voluntarily registered to donate bone marrow (REDOME). 
Individuals with chronic and acute diseases were excluded 
from the sample, as were those with a family history of ge-
netic disorders (X chromosome-linked diseases, autosomal 
diseases or chromosomal abnormalities).
Immunogenetic study
The DNA samples were extracted according to the salting 
out15 method and ampli¿ ed according to the polymerase chain 
reaction (PCR) technique. The sequence of primers for PCR 
has been described by Gómez-Lozano et al.16
The following mixture was used for DNA ampli¿ cation: 
1 ȝL of 10x buffer; 50 nM of MgCl2; 25 mM of dNTPs; 0.5 U 
taq polymerase; 10 Șg of DNA; 100 nm of internal control; 
and 500 mM of speci¿ c primer. The initial temperature for 
ampli¿ cation was 94ºC for 3 minutes. Then, there were 4 cycles 
of 15 seconds at 94ºC, 15 seconds at 65ºC, and 30 seconds 
at 72ºC. Then, there were 21 cycles of 15 seconds at 94ºC, 
15 seconds at 60ºC, and 30 seconds at 72ºC. To ¿ nish, 5 cycles 
of 15 seconds at 94ºC, 60 seconds at 55ºC, and 120 seconds at 
72ºC. The product was maintained for 420 seconds at 72ºC. 
The PCR product was analyzed by use of 1% agarose 
gel electrophoresis (p/v) and tris-acetate-EDTA (TAE) buf-
fer. Electrophoresis ran for 20 minutes at 200 V and room 
temperature. After electrophoresis was complete, the gel was 
stained with ethidium bromide, and the bands visualized and 
photographed under ultraviolet light.
Statistical analysis 
The model that predicts the activity of NK cells was applied as 
follows: a) KIR2DS1 and/or KIR2DS2 with homozygous HLA-
Cw for group 1 or 2 (combination of susceptibility – excessive 
activation); b) KIR2DS1 and/or KIR2DS2 with heterozygous 
HLA-Cw group; c) lack of KIR2DS1 or KIR2DS2 with homozy-
gous HLA-Cw group (relatively neutral combination – balance); 
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and d) lack of KIR2DS1 or KIR2DS2 with heterozygous HLA-
Cw group (combination of protection – excessive inhibition). The 
results were assessed by use of Pearson’s chi-square test and the 
SPSS 16.0 software. Statistical signi¿ cance was adopted as a P 
value  0.05.
RESULTS
Table 1 shows the patients’ genetic pro¿ le. Presence of all KIR 
genes tends to provide protection against the development of SSc. 
That genetic pro¿ le was evidenced in 1.77% of the patients with 
SSc as compared to 13.9% of the controls (P < 0.001). The other 
genetic pro¿ les showed no signi¿ cant difference. 
Activation of NK cells can be predicted by the possible 
combination of receptor activation or inhibition with the HLA-C 
molecule. That indicates that, depending on the genotype, an in-
dividual can have more over-active or balanced or over-inhibited 
NK cells. In this study, patients with SSc had excessive activation 
as compared with controls (Table 2). Of the 110 patients with SSc, 
34 (29.6%) had over-active NK cells as compared with 22 of 115 
(19.1%) controls. Analyzing excessive inhibition in each group, 
the control group had that pro¿ le more often. 
Previous studies have evidenced that the presence of the 
inhibitory KIR2DL2 gene might be related to protection against 
the development of SSc. To test that hypothesis, we strati¿ ed the 
patients according to the presence or absence of that gene (Table 
3). Considering only 2DL2-positive patients, we observed that the 
control group had excessive inhibition (34.7%) as compared to 
patients with the disease (10.9%), with a statistically signi¿ cant 
difference (< 0.001). Analyzing balanced or over-active NK cells 
in the presence of the 2DL2 gene, no statistically signi¿ cant dif-
ference was observed. Patients with SSc had 10.2% of excessive 
activation and 10% of balance, similarly to controls, who had 
16.5% and 11.3%, respectively. Assessing patients who lack the 
KIR2DL2 gene, different results were found. The frequency of 
excessive inhibition in patients (29.1%) is similar to that of the 
control group (26.1%). Thus, the balanced or excessively activated 
state of NK cells is less frequent in healthy individuals (2.6% and 
6.1%, respectively) as compared to patients with SSc (20.9% and 
20.9%, respectively).
DISCUSSION
Systemic sclerosis is a complex multifactorial disease. The most 
accepted hypothesis for its pathogenesis is that immune system 
activation is triggered by the interaction between environmental 
factors and genetic predisposition.17 Some genetic factors can 
inÀ uence the susceptibility to the development of SSc. Family 
history is the major risk factor identi¿ ed; however, the absolute 
risk for each family member is low (< 1%). The relative risk for 
Table 1
Frequency of the genetic pro¿ le of the KIR system in patients with systemic sclerosis (n = 110) and controls (n = 115)¥
KIR proﬁ le 2DL1 2DL2 2DL3 2DS1 2DS2 2DS3 2DS4 3DS1 3DL1 SSc (%) Control group (%)
#1 + − + − − − + − + 23.4 24.3
#2 + − + + − − + + + 4.34 7.0
#3 + − + - + − + − + 6.08 0.0
#4 + − + + + − + + + 1.77 0.0
#5 + + + + + + + + + 1.77a 13.9a
#6 + + + − + − + − + 9.73 13.9
#7 + − + − − − + + + 9.73 0.0
#8 + + − − − − + − + 0.0 6.1
#9 + + + + + − + + + 0.0 4.3
#10 + + + − + + + − + 2.6 4.3
#11 + + − − + + + − + 4.34 3.5
#12 + − + + + + + + + 5.21 0.0
#13 + − − − − − + − + 3.5 0.0
Others* 22.6 21.7
SSc: systemic sclerosis.
¥Statistical analysis performed with Fisher exact and Pearson’s chi-square tests. 
*Genetic proﬁ le observed in only one person was combined (others).
aP = 0.00085; odds ratio = 0.11; 95% conﬁ dence interval (0.012–0.497). The other genetic proﬁ les showed no statistical signiﬁ cance.
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¿ rst-degree relatives ranges from 10 to 16, and, for monozygous 
twins, from 10 to 27.18 Several studies have suggested that genetic 
susceptibility alone is not enough to induce disease. 
In our study, 9.73% of the patients with SSc had activating 
2DS2 and inhibitory 2DL2, and lack of activating 2DS1, 2DS3 
and 3DS1, as compared to 13.9% of the control group, and, thus, 
protection might also be provided by that pro¿ le. The pro¿ le 
‘absence of inhibitory 2DL2 and of activating 2DS1, 2DS2 and 
2DS3’ was found only in patients with SSc (9.73%). Conversely, 
the pro¿ le ‘presence of inhibitory 2DL2 and absence of the 
activating genes’ was only found in the control group (6.1%), 
and the presence of all genes (including the activating 2DS2 and 
inhibitory 2DL2) was more often found in the control group than 
in patients with SSc. Such data show the importance of inhibi-
tory 2DL2 for the development of SSc, and are in accordance 
with a previous study that showed an increase in the frequency 
of activating KIR2DS2 in the absence of inhibitory KIR2DL2 
in patients with SSc.19 Recently, using data of the same patients 
involved in the present study, we have reported a protective 
effect of the inhibitory 2DL2 gene against the development of 
SSc.20 That combination of KIR genes has also been observed 
in the pathogenesis of other rheumatic diseases. In rheumatoid 
arthritis, the presence of KIR2DS2 has been related to vasculi-
tis;21 in psoriatic arthritis, KIR2DS2 in the absence of KIR2DL2 
ligands has been associated with a higher risk of developing 
that disease.11 In addition, the involvement of the KIR2DS2+/
KIR2DL2í combination in the pathogenesis of Sjögren’s syn-
drome has been suggested.22
Recent studies have suggested that HLA-I genes might play a 
role in susceptibility to autoimmune diseases and their expression, 
such as rheumatoid arthritis, ankylosing spondylitis and systemic 
lupus erythematosus, through the interaction with KIR receptors. 
Based on the idea that an activating KIR, such as KIR2DS2, can 
favor the development of SSc in the absence of the ligand for any 
KIR2DL1 or KIR2DL2/3 (that is, homozygous for a group of 
HLA-Cw ligands), the novel model proposed by Nelson et al.10 
was used. That is in accordance with our understanding of KIR 
expression and function, and has a more robust statistical support 
for the role played by KIR in susceptibility to SSc than that of 
the previous model.
Previous studies associating the KIR genes in SSc have 
evidenced important results regarding susceptibility to that 
disease. However, no previous study has assessed the activity 
pro¿ le of NK cells in patients and controls – genes were assessed 
in isolation only. Our study showed that healthy individuals 
have excessive inhibition as compared to patients with SSc 
(P < 0.001). That is in accordance with a study performed with 
patients with diabetes,23 in which excessive inhibition was found 
in controls (25.71%) as compared to patients (1.02%). However, 
another study assessing that model in patients with psoriasis has 
reported no statistical difference between patients and controls 
(P = 0.822).12
Stratifying patients according to the gene associated with 
SSc (KIR2DL2), we found excessive inhibition in KIR2DL2-
positive controls (P < 0.001). When that gene was absent, there 
was prevalence of excessive activation (P < 0.001) and balance 
(P = 0.001) in patients with SSc, suggesting an important role of 
that gene in the development of SSc. Such observations further 
corroborate the hypothesis of a dominant protection provided by 
some inhibitory KIR genes. 
CONCLUSION
Imbalance between the number of activating/inhibitory KIR genes 
seems to play an important role in susceptibility to and protection 
against SSc. When certain models are used in data analysis, the 
interaction between KIR/HLA-C genes might indicate the role of 
NK cells in the pathology of SSc. Additional levels of variations, 
such as allelic polymorphisms, require further investigation, and 
new studies on the association of KIR genes with other autoim-
mune disorders are necessary. The results suggest that experiences 
with the function of NK cells can provide more information.
Table 2
Analysis of the activity of natural killer cells in patients with 
systemic sclerosis (n = 110) and control group (n = 115)
Controls SSc
P*
n % n %
Excessive activation 22 19.1 34 29.6
0.001Balance 20 17.4 36 31.3
Excessive inhibition 73 63.5 40 39.1
SSc: systemic sclerosis.
*Pearson’s chi-square test.
Table 3
Prediction of the activity of natural killer cells in patients 
and controls strati¿ ed according to the presence or absence 
of KIR2DL2
KIR2DL2 positive KIR2DL2 negative
EA B EI EA B EI
Controls 16.5% 11.3% 34.7% 2.6% 6.1% 26.1%
Patients 10.2% 10.0% 10.9% 20.9% 20.9% 29.1%
P* NS NS < 0.001 < 0.001 0.001 NS
EA: excessive activation; B: balance; EI: excessive inhibition; NS: non-signiﬁ cant.
*Pearson’s chi-square test.
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Quando estrati¿ camos os pacientes pelo gene que estava 
associado à ES (KIR2DL2), encontramos excesso de inibição 
nos controles com presença do KIR2DL2 (P < 0,001). Quando 
esse gene estava ausente, houve prevalência de excesso de 
ativação (P < 0,001) e de equilíbrio (P = 0,001) nos pacientes 
com ES, sugerindo papel importante desse gene no desen-
volvimento da doença. Essas observações corroboram ainda 
mais a hipótese de uma proteção dominante conferida por 
alguns genes KIR inibitórios. 
CONCLUSÃO
O desequilíbrio entre o número de KIR ativador/inibidor pa-
rece ser importante para a suscetibilidade e a proteção contra 
a doença. Se modelos perspicazes são utilizados na análise de 
dados, a interação entre os genes KIR/HLA-C pode indicar o 
papel das células NK na patologia da doença. Níveis adicio-
nais de variações, como polimor¿ smos alélicos, precisam ser 
investigados, assim como são necessários novos estudos de 
associação de genes KIR com outras desordens autoimunes. 
Os resultados sugerem que as experiências com a função das 
células NK podem ser mais informativas.
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